Trial Profile
Phase 4, Open-label, Non-randomized, Prospective Study of OZURDEX in the Treatment of Diabetic Macular Oedema - The AUSSIEDEX Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms The AUSSIEDEX Study
- Sponsors Allergan
- 01 Jan 2023 Results assessing the effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX; Ozurdex) monotherapy in the patient subgroup of the AUSSIEDEX study with treatment-naive diabetic macular oedema, published in the British Journal of Ophthalmology.
- 21 Jan 2019 Status changed from active, no longer recruiting to completed.
- 22 Oct 2018 Planned End Date changed from 30 Sep 2018 to 20 Oct 2018.